XERIS BIOPHARMA HOLDINGS, INC. Amortization of Debt Issuance Costs
XERIS BIOPHARMA HOLDINGS, INC. (XERS) reported Amortization of Debt Issuance Costs of $900.00 thousand for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AmortizationOfFinancingCosts · last filed 2026-08-06
- XERIS BIOPHARMA HOLDINGS, INC. amortization of debt issuance costs for the quarter ending 2026-06-30 was $900.00K, a 12.50% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of debt issuance costs for the quarter ending 2026-03-31 was $889.00K, a 5.33% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of debt issuance costs for the quarter ending 2025-12-31 was $866.00K, a 5.10% increase year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of debt issuance costs for the quarter ending 2025-09-30 was $800.00K, a 0.00% change year-over-year.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of debt issuance costs for fiscal 2025 was $3.37M, a 12.17% increase from fiscal 2024.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of debt issuance costs for fiscal 2024 was $3.01M, a 36.37% increase from fiscal 2023.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of debt issuance costs for fiscal 2023 was $2.21M, a 41.44% increase from fiscal 2022.
- XERIS BIOPHARMA HOLDINGS, INC. amortization of debt issuance costs for fiscal 2022 was $1.56M, a 62.23% increase from fiscal 2021.
| Period end | Amortization of Debt Issuance Costs 3 month | Amortization of Debt Issuance Costs 6 month | Amortization of Debt Issuance Costs 9 month | Amortization of Debt Issuance Costs 12 month |
|---|---|---|---|---|
| 2026-06-30 | $900.00K 10-Q · filed 2026-08-06 | $1.80M 10-Q · filed 2026-08-06 | $2.65M derived: sum of 3 quarters · filed 2026-08-06 | $3.46M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $889.00K 10-Q · filed 2026-05-07 | $1.75M derived: sum of 2 quarters · filed 2026-05-07 | $2.56M derived: sum of 3 quarters · filed 2026-05-07 | $3.35M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $866.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.67M derived: sum of 2 quarters · filed 2026-03-02 | $2.47M derived: sum of 3 quarters · filed 2026-08-06 | $3.37M 10-K · filed 2026-03-02 |
| 2025-09-30 | $800.00K 10-Q · filed 2025-11-06 | $1.60M derived: sum of 2 quarters · filed 2026-08-06 | $2.51M 10-Q · filed 2025-11-06 | $3.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $800.00K 10-Q · filed 2026-08-06 | $1.66M 10-Q · filed 2026-08-06 | $2.47M derived: sum of 3 quarters · filed 2026-08-06 | $3.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $844.00K 10-Q · filed 2026-05-07 | $1.67M derived: sum of 2 quarters · filed 2026-05-07 | $2.47M derived: sum of 3 quarters · filed 2026-05-07 | $3.27M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $824.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.62M derived: sum of 2 quarters · filed 2026-03-02 | $2.42M derived: sum of 3 quarters · filed 2026-03-02 | $3.01M 10-K · filed 2026-03-02 |
| 2024-09-30 | $800.00K 10-Q · filed 2025-11-06 | $1.60M derived: sum of 2 quarters · filed 2025-11-06 | $2.18M 10-Q · filed 2025-11-06 | $2.70M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-06-30 | $800.00K 10-Q · filed 2025-08-07 | $1.38M 10-Q · filed 2025-08-07 | $1.90M derived: sum of 3 quarters · filed 2026-03-02 | $2.50M derived: sum of 4 quarters · filed 2026-03-02 |
| 2024-03-31 | $573.00K 10-Q · filed 2025-05-08 | $1.10M derived: sum of 2 quarters · filed 2026-03-02 | $1.70M derived: sum of 3 quarters · filed 2026-03-02 | $2.30M derived: sum of 4 quarters · filed 2026-03-02 |
| 2023-12-31 | $527.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $1.13M derived: sum of 2 quarters · filed 2026-03-02 | $1.73M derived: sum of 3 quarters · filed 2026-03-02 | $2.21M 10-K · filed 2026-03-02 |
| 2023-09-30 | $600.00K 10-Q · filed 2024-11-08 | $1.20M derived: sum of 2 quarters · filed 2024-11-08 | $1.68M 10-Q · filed 2024-11-08 | $2.20M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $600.00K 10-Q · filed 2024-08-08 | $1.11M 10-Q · filed 2024-08-08 | $1.60M derived: sum of 3 quarters · filed 2025-03-06 | $2.00M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $548.00K 10-Q · filed 2024-05-09 | $996.00K derived: sum of 2 quarters · filed 2025-03-06 | $1.40M derived: sum of 3 quarters · filed 2025-03-06 | $1.90M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $448.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $848.00K derived: sum of 2 quarters · filed 2025-03-06 | $1.35M derived: sum of 3 quarters · filed 2025-03-06 | $1.56M 10-K · filed 2025-03-06 |
| 2022-09-30 | $400.00K 10-Q · filed 2023-11-09 | $900.00K derived: sum of 2 quarters · filed 2023-11-09 | $1.11M 10-Q · filed 2023-11-09 | $1.35M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-06-30 | $500.00K 10-Q · filed 2022-08-10 | $673.00K 10-Q · filed 2023-08-08 | $953.00K derived: sum of 3 quarters · filed 2024-03-06 | $1.19M derived: sum of 4 quarters · filed 2024-03-06 |
| 2022-03-31 | $219.00K 10-Q · filed 2023-05-09 | $453.00K derived: sum of 2 quarters · filed 2024-03-06 | $688.00K derived: sum of 3 quarters · filed 2024-03-06 | $929.00K derived: sum of 4 quarters · filed 2024-03-06 |
| 2021-12-31 | $234.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-06 | $469.00K derived: sum of 2 quarters · filed 2024-03-06 | $710.00K derived: sum of 3 quarters · filed 2024-03-06 | $961.00K 10-K · filed 2024-03-06 |
| 2021-09-30 | $235.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | $476.00K derived: sum of 2 quarters · filed 2022-11-09 | $727.00K 10-Q · filed 2022-11-09 | $1.00M derived: sum of 4 quarters · filed 2022-11-09 |
| 2021-06-30 | $241.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-10 | $492.00K 10-Q · filed 2022-08-10 | $765.00K derived: sum of 3 quarters · filed 2022-08-10 | |
| 2021-03-31 | $251.00K 10-Q · filed 2022-05-11 | $524.00K derived: sum of 2 quarters · filed 2022-05-11 | ||
| 2020-12-31 | $273.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-11 | $980.00K 10-K · filed 2022-03-11 | ||
| 2020-09-30 | $707.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |